Aurora Cannabis Inc. has entered into a definitive agreement with Organigram Global Inc. for a significant acquisition that will reshape the landscape of the cannabis industry. Under the agreement, Organigram will acquire all outstanding shares of Aurora for C$7.80 per share, providing Aurora shareholders with immediate value and future participation in the combined entity. This merger is poised to create a global leader in the cannabis market, enhancing both companies' capabilities and market reach.

The deal is particularly noteworthy as it comes amid a competitive landscape in the medicinal chemicals and botanical products sector. With this acquisition, Organigram and Aurora aim to leverage their complementary strengths to meet growing international demand and expand their global footprint.

Background

Aurora Cannabis Inc., traded under the ticker ACB on the Nasdaq, is a prominent player in the medicinal chemicals and botanical products industry, classified under SIC 2833. The company has been at the forefront of the cannabis revolution, focusing on high-quality products and innovative solutions. Recently, Aurora has faced challenges, including an unsolicited hostile bid from Curaleaf Holdings, which was unanimously rejected by its Board of Directors.

What the Filing Says

According to the recent filing dated November 3, 2026, Organigram's acquisition of Aurora is valued at approximately C$561 million on a fully diluted equity basis. The transaction offers Aurora shareholders a 93% premium over its unaffected share price prior to the Curaleaf bid and a 21% premium over Curaleaf's current bid value. The deal has received unanimous support from both companies' boards and is expected to enhance operational efficiencies and market presence.

Impact

This acquisition is set to significantly impact both Aurora and Organigram, as well as their shareholders. Aurora shareholders will have the option to receive cash, Organigram shares, or a combination of both, ensuring flexibility and value. The merger is expected to create a stronger platform for growth, with enhanced supply chain certainty and a broader international reach.

What's Next

The transaction is subject to shareholder approvals from both companies, with special meetings expected to be held in December 2026. Regulatory approvals and a court's sanction under the Business Corporations Act (British Columbia) will also be required. The merger is anticipated to close in January 2027, pending the satisfaction of all conditions.